Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA® biosimilar, available to patients
YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) — Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs or Mark Cuban … Read more